UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Volltextzugriff (PDF)

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Annals of oncology, 2017-12, Vol.28 (12), p.3044-3050

2017

Volltextzugriff (PDF)

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Annals of oncology, 2012-05, Vol.23 (5), p.1241-1249

2012

Volltextzugriff (PDF)

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Annals of oncology, 2023-11, Vol.34 (11), p.1047-1054

2023

Volltextzugriff (PDF)

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3461-3467

1999

Volltextzugriff (PDF)

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of oncology, 2023-03, Vol.34 (3), p.289-299

2023

Volltextzugriff (PDF)

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Annals of oncology, 2024-04, Vol.35 (4), p.392-401

2024

Volltextzugriff (PDF)

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

Journal of clinical oncology, 1999-03, Vol.17 (3), p.958-967

1999

Volltextzugriff (PDF)

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Journal of translational medicine, 2006-01, Vol.4 (1), p.1-1, Article 1

2006

Volltextzugriff (PDF)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

Annals of oncology, 2017-01, Vol.28 (1), p.90-95

2017

Volltextzugriff (PDF)

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer

Annals of oncology, 2020-07, Vol.31 (7), p.930-941

2020

Volltextzugriff (PDF)

Chemotherapy for advanced hormone refractory prostate cancer

Urology (Ridgewood, N.J.), 1999-12, Vol.54 (6), p.30-35

Petrylak, Daniel P

1999

Volltextzugriff (PDF)

Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression

Annals of oncology, 2018-10, Vol.29, p.viii331-viii331

2018

Volltextzugriff (PDF)

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Annals of oncology, 2018-10, Vol.29, p.viii326-viii327

2018

Volltextzugriff (PDF)

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

Annals of oncology, 2018-10, Vol.29, p.viii328-viii328

2018

Volltextzugriff (PDF)

Docetaxel (Taxotere) in hormone-refractory prostate cancer

Seminars in oncology, 2000-04, Vol.27 (2 Suppl 3), p.24

Petrylak, D P

2000

Volltextzugriff (PDF)

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii294-viii294

2018

Volltextzugriff (PDF)

Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point

Journal of clinical oncology, 2000-07, Vol.18 (13), p.2537-2544

2000

Volltextzugriff (PDF)

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Prostate cancer and prostatic diseases, 2014-09, Vol.17 (3), p.259-264

2014

Volltextzugriff (PDF)

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Volltextzugriff (PDF)

Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging

Clinical cancer research, 2000-06, Vol.6 (6), p.2146-2156

2000

Volltextzugriff (PDF)

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

ESMO open, 2021-04, Vol.6 (2), p.100082-100082, Article 100082

2021

Volltextzugriff (PDF)

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

Seminars in oncology, 1999-10, Vol.26 (5 Suppl 17), p.28-33

1999

Volltextzugriff (PDF)

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

The Journal of urology, 2000-03, Vol.163 (3), p.834-837

2000

Volltextzugriff (PDF)

Future directions in the treatment of androgen-independent prostate cancer

Urology (Ridgewood, N.J.), 2005-06, Vol.65 (6), p.8-12

Petrylak, Daniel P.

2005

Volltextzugriff (PDF)

1 – 25 von 231

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(201)

Publikationsform

Artikel
(229)
Tagungsberichte
(2)

Sprache

Englisch
(231)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(106)
Life Sciences & Biomedicine
(103)
Humans
(102)
Male
(82)
Oncology
(63)
Aged
(44)
Middle Aged
(43)
Biological And Medical Sciences
(42)
Medical Sciences
(41)
Urology & Nephrology
(40)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(32)
Chemotherapy
(32)
Prostatic Neoplasms - Drug Therapy
(31)
Tumors
(27)
Aged, 80 And Over
(26)
Treatment Outcome
(26)
Adult
(23)
Nephrology. Urinary Tract Diseases
(23)
Prostate Cancer
(23)
Prostatic Neoplasms - Pathology
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer

Chemotherapy for advanced hormone refractory prostate cancer

Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

Docetaxel (Taxotere) in hormone-refractory prostate cancer

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

Future directions in the treatment of androgen-independent prostate cancer

Aktive Filter

Suchergebnisse filtern